Indivior Pharmaceuticals (INDV) Gross Profit (2024 - 2026)

Indivior Pharmaceuticals' Gross Profit history runs 3 years deep, the most recent figure standing at $277.0 million for Q1 2026.

• In Q1 2026, Gross Profit rose 25.34% year-over-year to $277.0 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 12.55% YoY), while the FY2025 annual figure was $994.0 million, up 3.87% from the prior year.
• Gross Profit was $277.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $292.0 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $292.0 million in Q4 2025 to a low of $220.0 million in Q2 2024.
• Historically, Gross Profit has averaged $247.4 million across 3 years, with a median of $246.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Gross Profit declined 10.16% in 2025, then advanced 25.34% in 2026.
• A 3-year view of Gross Profit shows it stood at $250.0 million in 2024, then grew by 16.8% to $292.0 million in 2025, then decreased by 5.14% to $277.0 million in 2026.
• The last three Gross Profit figures came in at $277.0 million (Q1 2026), $292.0 million (Q4 2025), and $230.0 million (Q3 2025), per Business Quant data.